Optimising Management Of Injection-related Infections In People Who Inject Drugs
Funder
National Health and Medical Research Council
Funding Amount
$132,743.00
Summary
People who inject drugs are a vulnerable group who are at increased risk of bacterial infections, which can lead to serious illness and death. This project aims to optimize management of bacterial infections in people who inject drugs. Measuring the current burden of infections, analysing different management strategies employed in hospitals and discussing attitudes and barriers to care with both healthcare workers and people who inject drugs will provide the evidence to optimize ongoing care.
Establishing The Use Of Bacterial Genomics In Australia
Funder
National Health and Medical Research Council
Funding Amount
$157,669.00
Summary
We propose to establish a set of fully assembled reference genomes through new technologies and methods to analyse data from high throughput genome sequencing of important bacterial pathogens in Australia. We aim to demonstrate the capabilities of genome sequencing in clinical situations by comparing the genomes from clinical bacterial isolates to the established and annotated reference genomes.
Molecular Analysis Of Endocarditis Causing Strains Of Staphylococcus Aureus
Funder
National Health and Medical Research Council
Funding Amount
$110,960.00
Summary
"Staphylococcus aureus" or "Golden Staph” is one of the principal causes of infective endocarditis, the infection of the endocardial surfaces of the heart and heart valves that may result in valvular insufficiency and eventual heart failure. This work will define the molecular mechanisms that allow S. aureus to survive and persist on endocardial surfaces. Such insight may lead to new future treatment regimes for infective endocarditis.
Parasitic and viral infections involving the retina are serious eye conditions that are poorly understood and lack effective treatments. My PhD studies will focus on how human retinal cells fight infections caused by the Toxoplasma parasite, and dengue and Ebola viruses. The results of my investigations will inform the development of better treatments for these blinding eye diseases.
The Use Of Dosing Software With Bayesian Forecasting To Improve Antimicrobial-plasma Concentrations In The Intensive Care Unit
Funder
National Health and Medical Research Council
Funding Amount
$77,422.00
Summary
Emerging technologies such as DSBF is capable of assisting clinicians with selecting dosing regimens that achieve the target antimicrobial concentrations needed for treating infections. We will conduct a clinical trial to investigate the ability of DSBF to improve antimicrobial concentrations of patients in the ICU. The results of this study may lead to clinicians being given a new powerful validated tool for improving the treatment outcomes of patients suffering from infections in the ICU.
Clearing Chronic Infectious Diseases – Enhancing Host Immune Effector Function
Funder
National Health and Medical Research Council
Funding Amount
$92,314.00
Summary
Chronic infections produced by pathogens such as HIV, overwhelm our immune system leading to an exhausted state where cells responsible for the clearance of invading microorganisms are unable to respond effectively. We have recently identified a highly promising therapeutic target that enhances immune effector function. We seek to understand the underlying mechanism, and to explore the therapeutic potential of this approach for the treatment of a broad range of pathogens, including those respons ....Chronic infections produced by pathogens such as HIV, overwhelm our immune system leading to an exhausted state where cells responsible for the clearance of invading microorganisms are unable to respond effectively. We have recently identified a highly promising therapeutic target that enhances immune effector function. We seek to understand the underlying mechanism, and to explore the therapeutic potential of this approach for the treatment of a broad range of pathogens, including those responsible for chronic disease.Read moreRead less
Predicting Infections In Cancer Of The Plasma Cells In Bone Marrow (myeloma)
Funder
National Health and Medical Research Council
Funding Amount
$107,764.00
Summary
The study will look for new risks for infection in patients with multiple myeloma, a cancer of plasma cells in the bone marrow. Currently these patients are expected to live longer because of the discovery and use of new generation cancer drugs. By finding new infection risks, the treatment of life threatening infections can be improved or infection can be prevented so patients have a better quality of life whilst on cancer treatment.
Factors That Influence Disease Severity In Tuberculosis
Funder
National Health and Medical Research Council
Funding Amount
$149,076.00
Summary
Tuberculosis (TB) is a major global health problem and is one of the leading causes of death from an infectious disease worldwide. The severity of disease that occurs with TB is dependent on many complex factors including the infected person’s immune system and factors related to the TB organism itself. This research will determine the key factors that cause severe disease in TB which will translate into improved care of TB patients and enhance further research in this field.
Studies On The Pathogenesis And Early Diagnosis Of Hepatocellular Carcinoma
Funder
National Health and Medical Research Council
Funding Amount
$100,082.00
Summary
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and worldwide is the third and fifth leading cause of cancer death in men and women respectively. Early diagnosis is vital to patient survival. Our research investigates new methods in the early diagnosis of HCC, including new protein markers of the cancer and non-invasive measurements of liver scarring. We also study the genetics of HCC and investigate new genes that could be targets for future therapies.
Hepatitis B Virus Drug Resistance: Impact On The Immunisation Program
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
ñAntiviral drug-associated vaccine escape mutantsî have the potential to jeopardize the hepatitis B immunization program. Which particular viral mutations or combination of mutations that can directly affect the clinical outcome of infection, especially in the context of vaccine induced immunity, are not known. In this study we will identify the clinical sequelae and public health consequences arising from the selection of these mutants.